JPS63252251A - フロ−サイトメトリ−によるリンパ球の幼若化試験法 - Google Patents
フロ−サイトメトリ−によるリンパ球の幼若化試験法Info
- Publication number
- JPS63252251A JPS63252251A JP8753487A JP8753487A JPS63252251A JP S63252251 A JPS63252251 A JP S63252251A JP 8753487 A JP8753487 A JP 8753487A JP 8753487 A JP8753487 A JP 8753487A JP S63252251 A JPS63252251 A JP S63252251A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- lymphocytes
- lymphocyte
- fluorescence
- histogram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 64
- 238000012360 testing method Methods 0.000 title claims description 12
- 230000000638 stimulation Effects 0.000 claims abstract description 28
- 239000003226 mitogen Substances 0.000 claims abstract description 15
- 230000022131 cell cycle Effects 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 7
- 108010062580 Concanavalin A Proteins 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 39
- 238000000684 flow cytometry Methods 0.000 claims description 17
- 210000003855 cell nucleus Anatomy 0.000 claims description 14
- 239000007850 fluorescent dye Substances 0.000 claims description 12
- 230000006820 DNA synthesis Effects 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 210000000170 cell membrane Anatomy 0.000 claims description 9
- 230000004660 morphological change Effects 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 claims 2
- 230000001885 phytohemagglutinin Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 239000012228 culture supernatant Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 57
- 108010033737 Pokeweed Mitogens Proteins 0.000 abstract 2
- 239000000049 pigment Substances 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 230000035584 blastogenesis Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000013068 control sample Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000003716 rejuvenation Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000003822 cell turnover Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 241000209761 Avena Species 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101000993983 Nicotiana tabacum Proteinase inhibitor I-A Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000008216 juvenile development Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 102220234440 rs572685299 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8753487A JPS63252251A (ja) | 1987-04-09 | 1987-04-09 | フロ−サイトメトリ−によるリンパ球の幼若化試験法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8753487A JPS63252251A (ja) | 1987-04-09 | 1987-04-09 | フロ−サイトメトリ−によるリンパ球の幼若化試験法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63252251A true JPS63252251A (ja) | 1988-10-19 |
| JPH0562952B2 JPH0562952B2 (enExample) | 1993-09-09 |
Family
ID=13917653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8753487A Granted JPS63252251A (ja) | 1987-04-09 | 1987-04-09 | フロ−サイトメトリ−によるリンパ球の幼若化試験法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63252251A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023053574A1 (ja) * | 2021-09-29 | 2023-04-06 | 日東紡績株式会社 | 細胞または細胞核の豊富化方法 |
-
1987
- 1987-04-09 JP JP8753487A patent/JPS63252251A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023053574A1 (ja) * | 2021-09-29 | 2023-04-06 | 日東紡績株式会社 | 細胞または細胞核の豊富化方法 |
| JP7283642B1 (ja) * | 2021-09-29 | 2023-05-30 | 日東紡績株式会社 | 細胞または細胞核の豊富化方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0562952B2 (enExample) | 1993-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blaxhall et al. | Routine haematological methods for use with fish blood | |
| EP1262776B1 (de) | Verfahren zum quantitativen Nachweis vitaler ephithelialer Tumorzellen in einer Körperflüssigkeit | |
| Diamond et al. | Flow analysis of DNA content and cell size in non-Hodgkin's lymphoma | |
| FR2467402A1 (fr) | Methode d'essai biologique | |
| JPH061272B2 (ja) | 抗原と白血球細胞抗体間の反応程度を測定する方法及びその装置 | |
| SE442347B (sv) | Komposition for provning av biologiska vevnader eller vetskor innehallande ett dna-interaktivt fergemne och ett avexciterande emne, samt ett sett att anvenda kompositionen | |
| Ndako et al. | Evaluation of diagnostic assay of patients with enteric fever by the box-plot distribution method | |
| US3694161A (en) | Method for measuring platelet aggregation | |
| Farschtschi et al. | Advantages and challenges of differential immune cell count determination in blood and milk for monitoring the health and well-being of dairy cows | |
| Rosenberg et al. | Diagnostic performance of inflammatory markers in gopher tortoises (Gopherus polyphemus) | |
| Spink et al. | Diagnostic criteria for human brucellosis: Report No. 2 of the national research council, committee on public health aspects of brucellosis | |
| Spijkerman et al. | Refractory neutrophils and monocytes in patients with inflammatory bowel disease after repeated bouts of prolonged exercise | |
| JPS63252251A (ja) | フロ−サイトメトリ−によるリンパ球の幼若化試験法 | |
| Wiśniewska et al. | Detection of lymphatic vessels in dental pulp | |
| JP3258985B2 (ja) | 白血球活性酸素産生量及び酸化ストレスの測定方法 | |
| Fife Jr | Current state of serological tests used to detect blood parasite infections | |
| US3476514A (en) | Cancer cytoscreening | |
| RU2065167C1 (ru) | Способ диагностики предракового состояния вульвы | |
| Deutsch et al. | Fluorescence polarization as an early measure of T-lymphocyte stimulation | |
| RU2247374C1 (ru) | Способ прогнозирования эффективности терапии у больных лепрой | |
| RU2175769C2 (ru) | Способ определения стадии патологического процесса в тестах оценки функциональной активности лимфоцитов | |
| US7389132B2 (en) | Mold-in method and apparatus | |
| RU2079137C1 (ru) | Способ диагностики аллергии немедленного типа | |
| Smith | Body weight and the haematology of the American plaice Hippoglossoides platessoides | |
| RU2168175C1 (ru) | Способ диагностики инфекций |